UK-headquartered start-up Tenpoint Therapeutics has reeled in a commendable $70 million in first-round financing that will be used to develop its cell-based therapies for
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.